WorldCat Identities

Faria, José Custódio de 1756-1819

Overview
Works: 18 works in 46 publications in 4 languages and 131 library holdings
Genres: Criticism, interpretation, etc 
Roles: Author
Classifications: BF1132, 154.7
Publication Timeline
.
Most widely held works by José Custódio de Faria
De la cause du sommeil lucide ou Étude de la nature de l'Homme, 1819 by José Custódio de Faria( Book )

22 editions published between 1819 and 2005 in French and held by 64 WorldCat member libraries worldwide

Jose Custodio de Faria : hypnotist, priest and revolutionary : an annotated translation of Abbé Faria's On the cause of lucid sleep by Laurent Carrer( Book )

3 editions published between 1819 and 2005 in French and English and held by 4 WorldCat member libraries worldwide

C'est à José da Faria, connu sous le nom de l'abbé Faria (1756-1819), qu'appartient incontestablement le mérite d'avoir le premier établi la doctrine et la méthode de l'hypnose par suggestion et de l'avoir nettement dégagée des pratiques magiques. L'abbé Faria est en particulier le premier à nier l'existence du fluide magnétique ; à attribuer les phénomènes de somnambulisme à l'impressionnabilité psychique du sujet hypnotisé ; à découvrir le procédé suggestif ou psychique pour provoquer le somnambulisme ; à proposer une théorie psychologique pour expliquer les phénomènes du somnambulisme
Of the cause of lucid sleep or study of the nature of man = De la cause du sommeil lucide ou étude de la nature de l'homme by José Custódio de Faria( Book )

1 edition published in 2014 in English and held by 3 WorldCat member libraries worldwide

De adventu Sancti Spiritus oratio by José Custódio de Faria( Book )

2 editions published in 1775 in Undetermined and held by 2 WorldCat member libraries worldwide

Mémoire sur la vie de l'abbé de Faria : explication de la charmante légende du château d'If dans le roman Monte-Cristo by D. G Dalgado( Book )

1 edition published in 1906 in French and held by 2 WorldCat member libraries worldwide

De la cause du sommeil lucide ou étude de la nature de l'homme by José Custódio de Faria( Book )

1 edition published in 1812 in Undetermined and held by 1 WorldCat member library worldwide

Theologicae propositiones de existentia Dei, Deo uno et divina revelatione by Tommaso Maria Cerboni( Book )

1 edition published in 1780 in Latin and held by 1 WorldCat member library worldwide

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Background: Integrase strand transfer inhibitors (INSTIs) coadministered with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended as first-line treatment for HIV, and coformulated fixed-dose combinations are preferred to facilitate adherence. We report 48-week results from a study comparing initial HIV-1 treatment with bictegravir—a novel INSTI with a high in-vitro barrier to resistance and low potential as a perpetrator or victim of clinically relevant drug interactions—coformulated with the NRTI combination emtricitabine and tenofovir alafenamide as a fixed-dose combination to dolutegravir administered with coformulated emtricitabine and tenofovir alafenamide. Methods: In this randomised, double-blind, multicentre, placebo-controlled, non-inferiority trial, HIV-infected adults were screened and enrolled at 126 outpatient centres in 10 countries in Australia, Europe, Latin America, and North America. Participants were previously untreated adults (HIV-1 RNA ≥500 copies per mL) with estimated glomerular filtration rate of at least 30 mL/min. Chronic hepatitis B virus or hepatitis C co-infection was allowed. We randomly assigned participants (1:1) to receive oral fixed-dose combination bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or dolutegravir 50 mg with coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg, with matching placebo, once a day for 144 weeks. Investigators, participants, study staff, and those assessing outcomes were masked to treatment group. All participants who received at least one dose of study drug were included in primary efficacy and safety analyses. The primary endpoint was the proportion of participants with plasma HIV-1 RNA of less than 50 copies per mL at week 48 (US Food and Drug Administration snapshot algorithm), with a prespecified non-inferiority margin of −12%. This study is registered withClinicalTrials.gov, numberNCT02607956 . Findings: Between Nov 11, 2015, and July 15, 2016, 742 participants were screened for eligibility, of whom 657 were randomly assigned to treatment (327 with bictegravir, emtricitabine, and tenofovir alafenamide fixed-dose combination [bictegravir group] and 330 with dolutegravir plus emtricitabine and tenofovir alafenamide [dolutegravir group]). 320 participants who received the bictegravir regimen and 325 participants who received the dolutegravir regimen were included in the primary efficacy analyses. At week 48, HIV-1 RNA <50 copies per mL was achieved in 286 (89%) of 320 participants in the bictegravir group and 302 (93%) of 325 in the dolutegravir group (difference −3·5%, 95·002% CI −7·9 to 1·0, p=0·12), showing non-inferiority of the bictegravir regimen to the dolutegravir regimen. No treatment-emergent resistance to any study drug was observed. Incidence and severity of adverse events were similar between groups, and few participants discontinued treatment due to adverse events (5 [2%] of 320 in the bictegravir group and 1 [<1%] 325 in the dolutegravir group). Study drug-related adverse events were less common in the bictegravir group than in the dolutegravir group (57 [18%] of 320 vs 83 [26%] of 325, p=0·022). Interpretation: At 48 weeks, virological suppression with the bictegravir regimen was achieved and was non-inferior to the dolutegravir regimen in previously untreated adults. There was no emergent resistance to either regimen. The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide was safe and well tolerated compared with the dolutegravir regimen. Funding: Gilead Sciences Inc
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.85 (from 0.75 for Faria e Da ... to 0.98 for De adventu ...)

Jose Custodio de Faria : hypnotist, priest and revolutionary : an annotated translation of Abbé Faria's On the cause of lucid sleep
Alternative Names
Abbé de Faria

Abbe Faria

Abbé Faria Goan Catholic monk and pioneer of hypnotism

Abbé Faria personage uit De graaf van Monte-Cristo

Abbé Faria portugiesischer Priester, Hypnotiseur und einer der Begründer der Dynamischen Psychiatrie

Custódio de Faria José 1756-1819

Custodio, Joseph 1756-1819

Custodius de Faria Goano, Joseph 1756-1819

Custodius, Joseph 1756-1819

De Faria 1756-1819 Abade

De Faria 1756-1819 abbé

De Faria Abade

De Faria, Abade, 1756-1819

De Faria, abbé, 1756-1819

De Faria, José Custódio

De Faria, José Custódio 1756-1819

Faria 1756-1819 Abade de

Faria 1756-1819 abbé de

Faria, abade 1756-1819

Faria Abade de

Faria, Abade de, 1756-1819

Faria, Abbé 1756-1819

Faria Abbé de

Faria, abbé de, 1756-1819

Faria Goano, Joseph C. de 1756-1819

Faria, Jose Custodio de 1756-1819

Faria, Josephus C. de 1756-1819

José Custodio da Faria

José Custódio de Faria

Аббат Фариа

أبي فاريا

Languages
Covers